AnaptysBio to Host Virtual R&D Event on Rosnilimab, a Promising Immunology Therapeutic

AnaptysBio, a clinical-stage biotechnology company, is set to host a virtual R&D event for the investment community on rosnilimab, a PD-1 agonist antibody. The event will take place on October 25th and will feature independent medical experts and senior management from AnaptysBio.

Rosnilimab is a novel PD-1 checkpoint agonist antibody that aims to reduce overactive T cell inflammation. It has shown promising results with two distinct mechanisms of action, targeting PD-1+ T cells and impacting multiple drivers of disease pathogenesis. So far, the drug has been well-tolerated, with no dose-limiting toxicities or serious treatment-related adverse events reported.

During the virtual event, the medical experts and senior management will discuss the latest developments and potential applications of rosnilimab. The presentation will be followed by a Q&A session, allowing participants to gain further insights into the drug’s potential.

AnaptysBio is a clinical-stage biotechnology company focused on developing innovative immunology therapeutics. In addition to rosnilimab, the company is also developing ANB032, a BTLA agonist, for the treatment of moderate-to-severe atopic dermatitis. The company’s preclinical portfolio includes ANB033, an anti-CD122 antagonist antibody for autoimmune and inflammatory diseases.

Furthermore, AnaptysBio has two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, and etokimab, an anti-IL-33 antagonist. These drugs are currently in advanced stages of development for the treatment of specific conditions.

The company has also collaborated with GSK for immune-oncology, licensing multiple therapeutic antibodies, including anti-PD-1, anti-TIM-3, and anti-LAG-3 antagonist antibodies.

The virtual R&D event on rosnilimab will provide investors and the investment community with valuable insights into AnaptysBio’s innovative immunology therapeutics pipeline. The company’s dedication to developing novel treatments for autoimmune and inflammatory diseases demonstrates its commitment to improving patients’ lives.

For those interested in attending the event, a live webcast will be available on the investor section of the AnaptysBio website. Following the event, a replay of the webcast, along with supporting materials, will be accessible.

As AnaptysBio continues to advance its product candidates and explore potential partnerships, the company remains focused on achieving its development goals and bringing innovative immunology therapeutics to patients in need.